| David P Dichiara, MD | |
|
83 Herrick Street, Suite 2004, Beverly, MA 01915 | |
| (978) 927-4800 | |
| (978) 232-5772 |
| Full Name | David P Dichiara |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 40 Years |
| Location | 83 Herrick Street, Beverly, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477585461 | NPI | - | NPPES |
| 3035832 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VG0400X | Obstetrics & Gynecology - Gynecology | 58212 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northeast Hospital Corporation | Beverly, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Essex County Obgyn Assoc Inc | 6204829062 | 20 |
News Archive
Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore.
Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.
CellMax Life, enabling early cancer detection and management with affordable, non-invasive blood tests, announced today that six U.S. patents have been granted for its biomimetic platform CMx, which detects circulating tumor cells.
Now, Jefferson Lab scientists have used their expertise to build a small animal medical imager that's helping researchers develop a new gene therapy technique for cystic fibrosis.
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.
› Verified 1 days ago
| Entity Name | Essex County Obgyn Assoc Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538275870 PECOS PAC ID: 6204829062 Enrollment ID: O20040407000041 |
News Archive
Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore.
Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.
CellMax Life, enabling early cancer detection and management with affordable, non-invasive blood tests, announced today that six U.S. patents have been granted for its biomimetic platform CMx, which detects circulating tumor cells.
Now, Jefferson Lab scientists have used their expertise to build a small animal medical imager that's helping researchers develop a new gene therapy technique for cystic fibrosis.
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David P Dichiara, MD 83 Herrick Street, Suite 2004, Beverly, MA 01915 Ph: (978) 927-4800 | David P Dichiara, MD 83 Herrick Street, Suite 2004, Beverly, MA 01915 Ph: (978) 927-4800 |
News Archive
Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore.
Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.
CellMax Life, enabling early cancer detection and management with affordable, non-invasive blood tests, announced today that six U.S. patents have been granted for its biomimetic platform CMx, which detects circulating tumor cells.
Now, Jefferson Lab scientists have used their expertise to build a small animal medical imager that's helping researchers develop a new gene therapy technique for cystic fibrosis.
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.
› Verified 1 days ago
Deborah Bradley, Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 83 Herrick St, Suite 2004, Beverly, MA 01915 Phone: 978-927-4800 Fax: 978-232-5772 | |
Dr. Shiloe Souza Burzinski, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 83 Herrick St Ste 2004, Beverly, MA 01915 Phone: 978-927-4800 Fax: 978-777-4792 | |
Linda Kleeman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 75 Herrick St Ste 114, Beverly, MA 01915 Phone: 978-922-3000 | |
Laurel A Bauer, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 83 Herrick Street, Suite 2004, Beverly, MA 01915 Phone: 978-927-4800 Fax: 978-232-5772 | |
Melissa Jane Sherman, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 83 Herrick St, Suite 2004, Beverly, MA 01915 Phone: 978-927-4800 Fax: 978-232-5772 | |
Cara L Chuderewicz, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 83 Herrick Street, Suite 2004, Beverly, MA 01915 Phone: 978-927-4800 Fax: 978-232-5772 | |
Dr. Katrina Sanders, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 83 Herrick St, Suite 2004, Beverly, MA 01915 Phone: 978-927-4800 Fax: 978-232-5772 |